2025-524871-22-00CompletedPhase 4
Study to assess the relative bioavailability of Neludolat versus YAZ in healthy female subjects.
Pevisal Group Farmaceutici S.r.l.1 site in 1 country24 target enrollmentStarted: July 7, 2026Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 24
- Locations
- 1
Study Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Alessandro Allegrini
Scientific
Pevisal Group Farmaceutici S.r.l.
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A Phase 1 Study Evaluating Relative Bioavailability of Sprinkled Ritlecitinib in Applesauce, Yoghurt, and Strawberry Jam and Evaluating the Effect of Food on the Bioavailability of Ritlecitinib Intact Blend-In Capsule in Healthy Adult Participants.Alopecia Areata, Rheumatoid Arthritis, Vitiligo, Ulcerative Colitis and Crohn's Disease2022-502872-22-00Pfizer Inc.12
Recruiting
Phase 4
The pilot bioavailability study comparing the absorption of carbetocin (which is used as prevention of heavy bleeding after childbirth) in PABAL 100 μg/mL Solution for Injection when administered sublingually in the dose of 500 μg and intramuscularly in the dose of 100 μg.Not applicable (submitted trial is a bioavalability study in healthy participants).2025-524768-39-00Oxytone Bioscience B.V.4
Active, not recruiting
Phase 1
Evaluation of efficacy and bioavailability of ibuprofen lysinatePain on an inflammatory basis (otitis and otomastoiditis, adenite, cellulite, arthritis) and post-operative painMedDRA version: 21.0Level: PTClassification code 10050533Term: Pain assessmentSystem Organ Class: 10022891 - InvestigationsMedDRA version: 20.1Level: LLTClassification code 10063374Term: Pain scaleSystem Organ Class: 10022891 - InvestigationsEUCTR2019-000647-27-ITDicofarm S.p.A.84
Recruiting
Phase 1
A study to assess the safety, and blood levels of CTX-187 after single and repeated intravenous doses in healthy volunteers and patients with bacterial infectionBacterial Infection2026-525619-15-00Centauri Therapeutics Limited68
Recruiting
Phase 1
To evaluate the pharmacokinetics and safety of nolasibannot applicable (submitted trial is a pharmacokinetic study in healthy subjects)2025-523706-32-00ReproNovo ApS28